Classification
- Anatomical main groupLAntineoplastic and immunomodulating agents
- Therapeutic subgroupL01Antineoplastic agents
- Pharmacological subgroupL01F
- Chemical subgroupL01FF
- Chemical substanceL01FF03Durvalumab
Where it is registered
Each register and historical list with its number of registrations and a few of them.
Spain
AEMPS · 6 registrations
- Imfinzi 50 MG/ML Concentrado Para Solucion Para Perfusion120 mg · concentrado para solución para perfusión · Astrazeneca Ab · 2 entries
- Imfinzi 50 MG/ML Concentrado Para Solucion Para Perfusion500 mg · concentrado para solución para perfusión · Astrazeneca Ab · 2 entries
New Zealand
PHARMAC (NZ funding schedule) · 2 registrations
Serbia
ALIMS · 2 registrations
At a glance
- ATC code
- L01FF03
- Registers
- 10
- Historical lists
- 2
- Registrations
- 21
- With their own page
- 18
- Companies
- 6
All medicines with Durvalumab
Human medicines from every register that match Durvalumab by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
21 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Imfinzi | United States | 50MG/ML | injectable | Marketed | Astrazeneca UK LTD |
| Imfinzi | United States | 120MG/2.4ML | Injection | Marketed | AstraZeneca UK Ltd |
| Imfinzi | European Union | Authorised | AstraZeneca AB | ||
| Imfinzi 50 MG/ML Concentrado Para Solucion Para Perfusion | Spain | 120 mg | concentrado para solución para perfusión | Marketed | Astrazeneca Ab |
| Imfinzi 50 MG/ML Concentrado Para Solucion Para Perfusion | Spain | 500 mg | concentrado para solución para perfusión | Marketed | Astrazeneca Ab |
| Imfinzi 50 MG/ML Concentrado Para Solucion Para Perfusion | Spain | 500 mg | concentrado para solución para perfusión | Marketed | Astrazeneca Ab |
| Imfinzi 50 MG/ML Concentrado Para Solucion Para Perfusion | Spain | 120 mg | concentrado para solución para perfusión | Marketed | Astrazeneca Ab |
| Imfinzi 50 MG/ML Concentrado Para Solucion Para Perfusion | Spain | 120 mg | concentrado para solución para perfusión | Marketed | Astrazeneca Ab |
| Imfinzi 50 MG/ML Concentrado Para Solucion Para Perfusion | Spain | 500 mg | concentrado para solución para perfusión | Marketed | Astrazeneca Ab |
| Imfinzi 50 mg/ml, concentraat voor oplossing voor infusie | Netherlands | Concentraat voor oplossing voor infusie | Authorised | AstraZeneca AB | |
| Imfinzi | Canada | 50 MG / ML | Solution | Marketed | Astrazeneca Canada INC |
| Imfinzi | Brazil | Authorised | Astrazeneca do Brasil Ltda | ||
| Imfinzi Concentrate for Solution for Infusion 50 MG/ML | Singapore | 50 mg/ml | infusion, solution concentrate | Authorised | Astrazeneca Singapore Pte LTD |
| Imfinzi® | Serbia | 50mg/ml | koncentrat za rastvor za infuziju | Authorised | PredstavniŠTvo Astrazeneca UK Limited Beograd |
| Imfinzi® | Serbia | 50mg/ml | koncentrat za rastvor za infuziju | Authorised | PredstavniŠTvo Astrazeneca UK Limited Beograd |
| Imfinzi | Croatia | Marketed | |||
| Imfinzi | New Zealand | Inj 50 mg per ml, 2.4 ml vial | Funded | ||
| Imfinzi | New Zealand | Inj 50 mg per ml, 10 ml vial | Funded | ||
| IMFINZI 120 mg / 2.4 ml | Saudi Arabia | Authorised | AstraZeneca Pharmaceuticals LP | ||
| IMFINZI 500 mg / 10 ml | Saudi Arabia | Authorised | AstraZeneca Pharmaceuticals LP | ||
| IMFINZI 50 mg/ml | Romania | 50mg/ml | conc. pt. sol. perf. | Status unknown | Astrazeneca AB |